avelumab联合立体定向消融放疗治疗转移性去势抵抗性前列腺癌:II期ICE-PAC临床试验
这项II期研究纳入31例经至少一种雄激素受体靶向治疗后进展的mCRPC患者,给予avelumab联合SABR治疗,主要终点疾病控制率为48%,客观缓解率为31%,中位rPFS为8.4个月,中位OS为14.1个月,3-4级治疗相关不良事件发生率为16%,提示该联合方案在难治性mCRPC中具有初步疗效且毒性可接受。
要点
- avelumab联合SABR在经多线治疗的mCRPC中疾病控制率达48%,客观缓解率31%。
- 中位rPFS为8.4个月,中位OS为14.1个月,3-4级治疗相关不良事件发生率16%。
- 血浆雄激素受体改变与较低疾病控制率相关(22% vs 71%,p=0.13)。
核心结论
- avelumab联合SABR在难治性mCRPC中显示出令人鼓舞的活性和可接受的毒性,值得进一步研究。
研究设计与样本
- 前瞻性II期单臂研究,2017年11月至2019年7月入组31例经至少一种雄激素受体靶向治疗后进展的mCRPC男性,中位随访18.0个月。
主要发现
- 疾病控制率为48%(15/31,95%CI 30-67%),客观缓解率为31%(5/16,95%CI 11-59%)。
- 未照射病灶的客观缓解率为33%(4/12,95%CI 10-65%)。
- 中位影像学无进展生存期为8.4个月(95%CI 4.5-未达到),中位总生存期为14.1个月(95%CI 8.9-未达到)。
- 3-4级治疗相关不良事件发生于6例(16%),其中3例(10%)需要高剂量皮质类固醇治疗。
- 血浆雄激素受体改变与较低疾病控制率相关(22% vs 71%,p=0.13,Fisher精确检验)。
临床怎么用
- 对于经多线治疗的mCRPC患者,avelumab联合SABR可作为潜在治疗选择,但需进一步研究验证。
局限性
- 样本量小且无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be synergistic with checkpoint inhibitors. OBJECTIVE: To evaluate the efficacy and safety of the PD-L1 inhibitor avelumab with stereotactic ablative body radiotherapy (SABR) in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: From November 2017 to July 2019, this prospective phase 2 study enrolled 31 men with progressive mCRPC after at least one prior androgen receptor-directed therapy. Median follow-up was 18.0 mo. INTERVENTION: Avelumab 10 mg/kg intravenously every 2 wk for 24 wk (12 cycles). A single fraction of SABR (20 Gy) was administered to one or two disease sites within 5 d before the first and second avelumab treatments. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the disease control rate (DCR), defined as a confirmed complete or partial response of any duration, or stable disease/non-complete response/non-progressive disease for ≥6 mo (Prostate Cancer Clinical Trials Working Group 3-modified Response Evaluation Criteria in Solid Tumours version 1.1). Secondary endpoints were the objective response rate (ORR), radiographic progression-free survival (rPFS), overall survival (OS), and safety. DCR and ORR were calculated using the Clopper-Pearson exact binomial method. RESULTS AND LIMITATIONS: Thirty-one evaluable men were enrolled (median age 71 yr, 71% with ≥2 prior mCRPC therapy lines, 81% with >5 total metastases). The DCR was 48% (15/31; 95% confidence interval [CI] 30-67%) and ORR was 31% (five of 16; 95% CI 11-59%). The ORR in nonirradiated lesions was 33% (four of 12; 95% CI 10-65%). Median rPFS was 8.4 mo (95% CI 4.5-not reached [NR]) and median OS was 14.1 mo (95% CI 8.9-NR). Grade 3-4 treatment-related adverse events occurred in six patients (16%), with three (10%) requiring high-dose corticosteroid therapy. Plasma androgen receptor alterations were associated with lower DCR (22% vs 71%, p = 0.13; Fisher's exact test). Limitations include the small sample size and the absence of a control arm. CONCLUSIONS: Avelumab with SABR demonstrated encouraging activity and acceptable toxicity in treatment-refractory mCRPC. This combination warrants further investigation. PATIENT SUMMARY: In this study of men with advanced and heavily pretreated prostate cancer, combining stereotactic radiotherapy with avelumab immunotherapy was safe and resulted in nearly half of patients experiencing cancer control for 6 months or longer. Stereotactic radiotherapy may potentially improve the effectiveness of immunotherapy in prostate cancer.
引用
- Kwan EM, Spain L, Anton A, et al. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. Eur Urol. 2021. PMID: 34493414. doi:10.1016/j.eururo.2021.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。